The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings

BioNTech (BNTX) Stock May Be Above Fair Value After Lung Cancer Data

Why Is BioNTech Stock Falling Today? - BioNTech (NASDAQ:BNTX)

Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady

BioNTech Evaluates Next Steps as Breast Cancer Drug Shows Limited Patient Benefit

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

BioNTech SE (BNTX) stock price, news, quote and history

BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?

BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

Moderna’s Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure

Moderna’s Cancer-Vaccine Leak Spurs Panic Selling. Wall Street Wanted a Cure.

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

BioNTech Enters Clinical Trial Collaboration And Supply Agreement With Gilead Sciences To Evaluate Pumitamig In Combination With Sacituzumab Govitecan As First-Line Treatment For Patients With Locally Advanced Or Metastatic PD-L1 Low Or Negative Triple-negative Breast Cancer